BioNexus Gene Lab Corp.

What they do

The company operates through two wholly owned Malaysian subsidiaries. Chemrex Corporation Sdn. Bhd. distributes chemical raw materials for industrial, medical, appliance, aero, automotive, mechanical and electronic manufacturing across Malaysia, Indonesia, Vietnam and other Southeast Asian markets. MRNA Scientific Sdn. Bhd. runs blood-based genomic screening services that analyze RNA biomarkers for disease risk assessment. In November 2025 the company acquired exclusive perpetual ASEAN commercial rights to the VitaGuard AI-enabled minimal residual disease liquid biopsy platform.

Revenue drivers

• Chemrex industrial chemical distribution — Wholesale of chemical raw materials in the ASEAN region is the company's historical revenue base, and management attributes fiscal 2025's decline primarily to lower Chemrex sales volume.
• MRNA Scientific genomic screening services — Blood-based RNA biomarker screening and related laboratory services; the company says it continues to evaluate this unit's operations, commercial opportunities and strategic direction.
• VitaGuard MRD platform (licensed) — Exclusive perpetual ASEAN license to an AI-enabled minimal residual disease monitoring platform; deployment phase commenced January 2026, and the company committed to purchase at least $500,000 of VitaGuard reagents and system components in the first 24 months.

Recent performance

Quarterly revenue has collapsed sharply, from $2.5M in the quarter ended 2025-09-30 to $483,760 in 2025-12-31, $22,842 in 2026-03-31 and $76,156 in 2026-06-30. Annual revenue fell from $13.4M in 2021 to $9.5M in 2024 and $7.4M in 2025. Net income was negative $3.0M in 2025, versus negative $1.6M in 2024 and negative $2.6M in 2023. Operating cash flow was negative $1.8M in 2025, $2.1M in 2024 and $1.8M in 2023. At 2026-06-30 the company reported total assets of $8.7M, total liabilities of $947,981, shareholder equity of $7.8M and cash and equivalents of $1.2M.

Strategy

Management's stated priorities are modernizing and rebuilding the blood-based genomic screening platform through GeneMatrix Systems, advancing VitaGuard commercialization with Fidelion, stabilizing Chemrex trading and collections, and evaluating strategic options under disciplined capital allocation. In November 2025 the company signed a Share Subscription and Shareholders' Agreement to acquire at least 15.0% of Fidelion's enlarged share capital in exchange for issuing Fidelion 392,329 shares, equal to 19.9% of the company's then-outstanding common stock. It also entered an Equity Purchase Agreement with ARC Group International Ltd. for up to $500,000,000 of common stock over 36 months and an at-the-market program with Maxim Group LLC. The 10-K cites ongoing governance and internal control remediation at Chemrex and $2,000,000 in VitaGuard license fees payable to Fidelion in 24 monthly installments.

Risks

• Declining revenue and recurring losses — Annual revenue fell every year from $13.4M in 2021 to $7.4M in 2025 while net losses reached $3.0M in 2025 and quarterly revenue dropped to $76,156 by 2026-06-30.
• Liquidity and financing dependence — The 10-K states liquidity depends on managing operating cash usage and access to capital, with working capital declining to $4,927,781 at December 31, 2025 from $5,479,146, and no assurance that financing will be available on acceptable terms.
• VitaGuard license obligations and commercialization risk — The company owes Fidelion $2,000,000 in license fees over 24 monthly installments plus a minimum $500,000 VitaGuard reagent and component purchase commitment, while the platform is still in a deployment and planning phase.
• Governance and internal control issues at Chemrex — The 10-K describes historical control and approval issues at Chemrex and ongoing remediation efforts, and notes the company faced potential Nasdaq delisting over a Bid Price deficiency that was remedied after a 1-for-10 reverse split effective April 7, 2025.

Outlook

Management says its plans to address liquidity include improving Chemrex operating performance, controlling discretionary expenditures, continuing remediation of internal controls and governance, and pursuing external financing and capital markets transactions where available. The company also states it expects to incur significant costs to market the VitaGuard platform in ASEAN. It cautions that additional financing may not be available on acceptable terms, that equity financing could be dilutive, and that debt could impose restrictive covenants.